The Idiopathic (Essential) Hypertension drugs in development market research report provides comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Idiopathic (Essential) Hypertension. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Idiopathic (Essential) Hypertension and features dormant and discontinued products.
GlobalData tracks 57 drugs in development for Idiopathic (Essential) Hypertension by 36 companies/universities/institutes. The top development phase for Idiopathic (Essential) Hypertension is phase iii with 25 drugs in that stage. The Idiopathic (Essential) Hypertension pipeline has 57 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Idiopathic (Essential) Hypertension pipeline products market are: Addpharma, Hanmi Pharmaceuticals and Boryung Pharmaceutical.
The key targets in the Idiopathic (Essential) Hypertension pipeline products market include Type 1 Angiotensin II Receptor, Voltage Dependent L Type Calcium Channel, and Solute Carrier Family 12 Member 3.
The key mechanisms of action in the Idiopathic (Essential) Hypertension pipeline product include Type 1 Angiotensin II Receptor Antagonist with 14 drugs in Pre-Registration. The Idiopathic (Essential) Hypertension pipeline products include five routes of administration with the top ROA being Oral and three key molecule types in the Idiopathic (Essential) Hypertension pipeline products market including Small Molecule, and DNA Vaccine.
Idiopathic (Essential) Hypertension overview
Idiopathic hypertension, also known as essential hypertension, refers to high blood pressure without an identifiable underlying cause. It is a common chronic medical condition characterized by persistently elevated blood pressure levels that can potentially lead to cardiovascular complications if left uncontrolled. Idiopathic hypertension is the most prevalent type of hypertension, affecting a significant portion of the population. It typically develops gradually over time and tends to occur more frequently in adults but can also affect children and adolescents. Causes are thought to be a combination of genetic, environmental, and lifestyle factors, including genetic predisposition, obesity or overweight, unhealthy diet (particularly one high in sodium and low in potassium), sedentary lifestyle or lack of regular physical activity, stress and certain psychological factors, and aging. Essential hypertension is often asymptomatic in its early stages, which makes it sometimes referred to as a “silent killer.” Many people with high blood pressure may not experience noticeable symptoms until it reaches significantly elevated levels or leads to complications. Some individuals might experience headaches, dizziness, or nosebleeds in severe cases.
For a complete picture of Idiopathic (Essential) Hypertension’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
